Antanan ® in China to treat Huntington's disease and delayed movement disorder

Huntington's disease is a rare and deadly neurodegenerative disease that affects about 0.4 out of every 100,000 people in Asia, with an average age of 40.
- unconscious, random and sudden, twisting and/or rotating motion - is one of the most pronounced manifestations of the disease and occurs in about 90% of patients.
Wu Zhiying, vice president of the Second Hospital affiliated with Zhejiang University School of Medicine and director of the Neurology Research Center, said: "Huntington's disease has no special effects drugs, and the current treatment is mainly empirical treatment."
Antaltan® is currently one of the few drugs in the world that is considered to control the symptoms of Huntington's (HD) dance disease, entering China will enrich the clinical treatment options for doctors, this time included in the health insurance is also a public expectation, which is a testament to the importance that the state attaches to the group of patients with rare diseases.
" delayed movement disorder (TD) is a debilitating movement disorder characterized by repeated and uncontrollable movements of the tongue, lips, face, body, and limbs.
TD has a 33.7 percent prevalence rate among people with schizophrenia in China who have been treated with antipsychotic drugs for a long time, possibly caused by certain drugs used to treat mental health conditions, meaning that one-third of people with schizophrenia who use these drugs may have TD.
the disease not only affects the patient's therapeutic compliance, but also affects the patient's quality of life and their social function.
there is currently no treatment for TD in China.
can significantly ® abnormal involuntary movement and good tolerance in patients with TD, giving patients hope of improving quality of life and social function.
"We are very grateful to the National Drug Administration's Drug Review Center for the importance it attaches to innovative drugs for rare diseases, which has led to the inclusion of Antanic ® in the list of clinically urgently needed new drugs from abroad (the first batch) and its entry into the priority review and approval process, making China the second country in the world to approve the drug after the United States in just four months."
Addition, The rapid launch and health care breakthrough of Antany ® is the result of our continuous bringing innovative products to China and our efforts to improve drug access, and an important milestone in our strategy to achieve China.
," said Larry E. Merizalde, general manager of Teva Greater China.
is also extremely exciting for Teva to introduce new treatments to meet the unfinished needs of patients. Gianfranco Nazzi, executive vice president of global markets at
Teva, added, "As a global leader in generics and specialty medicines, we are committed to delivering high-quality, innovative drugs that improve drug access and improve the quality of life of our patients."
, we will continue to focus on the most urgent clinical needs of Chinese patients, actively working with partners from all walks of life to accelerate the introduction of innovative drugs to help achieve the "Healthy China 2030" vision.
" about Antany®Antas® was approved by the FDA in April 2017, the first FDA-approved niobium product and the second drug in history for hunting disease related to Huntington's disease.
, the drug has been approved in the U.S. and China, where approved allergies include hunting disorders related to Huntington's disease (HD) and delayed movement disorders (TDs) in adults.
FDA's approval of Antittan ® represents an important new treatment option for HD patients and highlights the need for more treatment resources for this under-serviced patient population, with TD adaptation approved as a breakthrough treatment.
we believe that doctors treating late-oncward movement disorders will appreciate the dose flexibility of the treatment and the ability to focus directly on treating motor disorders without undermining ongoing treatment for underlying diseases.
The approved clinical trial for dance disease associated with Huntington's disease, Antany® was approved for the treatment of dance disease related to Huntington's disease, based on a randomized, double-blind, placebo-controlled, multi-center trial involving 90 people with dance disease associated with significant Huntington's disease, with the highest overall clinical evaluation index for dance disease symptoms (Total Maximal Chorea Score, TMC score).
results showed that antatins ®: - had significant therapeutic effects: the average TMC score improvement in the xenodybenol group was 4.4 (placebo group 1.9, P<0.0001), and the proportion of patients with a TMC score reduction of more than 6 points was 33% (2% in the placebo group).
according to the Unified Assessment Scale (Unified Huntington Disease Rating Scale, UHDRS), the average improvement in the xenobenazine group was 7.4 (placebo group 3.4, P=0.002).
- Treatment success rates can be significantly improved: according to patients' overall impression change scale (Patient Global Impression of Change, PGIC), the success rate of treatment in the xydybenazine group was 51% (placebo group 20%, P=0.002);
- There was no statistical difference with the placebo control group, and the risk of neuropsychiast events was lower in patients who started treatment.
Clinical trials on delayed movement disorders in adults, Antanium ® approved for the treatment of delayed movement disorders in adults, are based on the results of two Phase III randomized, double-blind, placebo-controlled, parallel group studies that demonstrate antitamines ®: - With significant therapeutic effects: treatment of abnormalities in the 12th week of the group The improvement in involuntary exercise (Abnormal Involuntary Movement, AIMS) score was 3.3 (placebo group 1.5, P.lt;0.001) and 33 percent of patients with AIMS score reduction of more than 50 percent (placebo group 12 percent, P.007).
- Treatment success rates can be significantly improved: In a comprehensive analysis in the ARM-TD and AIM-TD studies, patients treated with pyridine were more than twice as likely to be successful at week 12 (2.1; P-0.005), and patients with xydybenzene had an average CGIC score (48%) higher than those with good safety and resistance to placebo (30%).
no negative effects on the measurement of drowsiness, weight, or heart metabolic factors.